Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | ANPEP | P15144 | 2/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.38 |
| ▸ | DPP4 | P27487 | 5/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21682451 | 1.00 | MMP2 (0.54) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL18339420 | 1.00 | MMP2 (0.54) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL19744399 | 1.00 | MMP2 (0.54) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL29260191 | 1.00 | MMP2 (0.54) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL16171925 | 0.87 | MMP2 (0.71) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL28539537 | 0.85 | MMP2 (0.42) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL29162169 | 0.85 | MMP2 (0.42) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL25368206 | 0.83 | MMP2 (0.41) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL29930727 | 0.83 | MMP2 (0.41) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL29930529 | 0.83 | MMP2 (0.41) | MMP2ANPEPDPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239769-A1 | CO-CRYSTAL OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND VANILLIN AND METHOD FOR PREPARING SAME | LG CHEM, LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-20240239782-A1 | SULFATE CRYSTALS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PRODUCING SAME | LG CHEM, LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-20240239783-A1 | CRYSTAL FORM VII OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME | LG CHEM, LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-20240228473-A1 | CRYSTALLINE FORM V OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND METHOD FOR PREPARING SAME | LG CHEM, LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| US-20240217954-A1 | CRYSTAL FORM IV OF ORGANIC ACID SALTS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND PREPARATION METHOD THEREOF | LG CHEM, LTD. (KR) | 2024-07-04 | — | — | US | disclosed |
| EP-4384520-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| US-20240190856-A1 | MELANOCORTIN-4 RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2024-06-13 | — | — | US | disclosed |
| US-20240058303-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | RES TRIANGLE INST (US) | 2024-02-22 | — | — | US | disclosed |
| US-20240059652-A1 | AMORPHOUS MELANOCORTIN RECEPTOR AGONIST AND METHOD FOR PREPARING SAME | LG CHEM, LTD. (KR) | 2024-02-22 | — | — | US | disclosed |
| US-20240051919-A1 | CRYSTALLINE FORM III OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR | LG CHEM, LTD. (KR) | 2024-02-15 | — | — | US | disclosed |
| CN-110546136-A | proline-based neuropeptide FF receptor modulators | RES TRIANGLE INST | 2019-12-06 | — | — | CN | disclosed |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190322645-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3472151-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3472130-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3472149-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017222917-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017222915-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017222914-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217954-A1 | CRYSTAL FORM IV OF ORGANIC ACID SALTS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND PREPARATION METHOD THEREOF | MC4R, MC3R, MC5R | MMP2 2668/4885ANPEP 4443/4885DPP7 2335/4885 |
| US-20240239782-A1 | SULFATE CRYSTALS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PRODUCING SAME | MC1R, MC5R, MC3R | MMP2 4296/4885ANPEP 2576/4885DPP7 1891/4885 |
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ADCYAP1R1, HTRA2 | MMP2 92/4885ANPEP 238/4885DPP7 31/4885 |
| US-20190322645-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ALDH1A2, HTRA2 | MMP2 145/4885ANPEP 279/4885DPP7 46/4885 |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | HTRA1, ALDH1A2, PREP | MMP2 145/4885ANPEP 95/4885DPP7 49/4885 |
| US-20240228473-A1 | CRYSTALLINE FORM V OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND METHOD FOR PREPARING SAME | MC5R, MC1R, MC3R | MMP2 3969/4885ANPEP 2577/4885DPP7 2496/4885 |
| US-20240239769-A1 | CO-CRYSTAL OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND VANILLIN AND METHOD FOR PREPARING SAME | MC1R, MC5R, MC3R | MMP2 4335/4885ANPEP 3162/4885DPP7 2252/4885 |
| US-20240190856-A1 | MELANOCORTIN-4 RECEPTOR AGONIST | MC4R, MC5R, MC3R | MMP2 3417/4885ANPEP 1433/4885DPP7 594/4885 |
| US-20240058303-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | NPFFR1, NPFFR2, NPBWR1 | MMP2 2459/4885ANPEP 93/4885DPP7 214/4885 |
| US-20240051919-A1 | CRYSTALLINE FORM III OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR | MC3R, MC1R, MC5R | MMP2 4347/4885ANPEP 3692/4885DPP7 711/4885 |
| US-20240059652-A1 | AMORPHOUS MELANOCORTIN RECEPTOR AGONIST AND METHOD FOR PREPARING SAME | MC3R, MC5R, MC2R | MMP2 4649/4885ANPEP 1533/4885DPP7 1932/4885 |
| US-20240239783-A1 | CRYSTAL FORM VII OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME | MC5R, MC1R, MC3R | MMP2 3818/4885ANPEP 2647/4885DPP7 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.